Share

EORTC abstracts selected at ESMO 2019

In total, EORTC will be presenting 3 abstracts (2 oral presentations and 1 poster) at the ESMO Congress 2019 from 27 September until 1 October in Barcelona, Spain.

Andrew Bottomley, Head of the Quality of Life at EORTC, will chair a session about “Surviving a cancer diagnosis with a good QoL” on 30 September from 8:30 to 10:00 and give a lecture on “Can value frameworks (such as ESMO-MCBS) contribute to a higher QoL?”

During the same session, Madeline Pe, EORTC Specialist in QoL, will talk about EORTC’s work on survivorship.

Meet us at our booth located in the society village n°20.

 

Oral presentations

A phase II study of Monalizumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): results of the I1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)

R Galot, C Le Tourneau, E Saada-Bouzid, A Daste, C Even, P Debruyne, S Henry, S Zanetta, A Rutten, L Licitra, JL Canon, MC Kaminsky, P Specenier, S Rottey, L Dirix, T Raveloarivahy, C Fortpied, M Vanlancker, A Govaerts, JP Machiels  

Presentation number: 1109O

Speaker: Rachel Galot

Date: 30.09.2019 – Lecture time: 10:15 – 11:45 – Location: Cordoba Auditorium (Hall 7)

Redefining the IGCCCG Classification in advanced Non-Seminoma

Gillessen S, Collette L, Daugaard G, De Wit R, Tryakin A, Albany C, Stahl O, Fizazi K, Gietema J, De Giorgi U, Hansen AR,  Feldman D, Cafferty FH, Tandstad T, Garcia del Muro X, Huddart R, Sweeney C, Heng DY, Sauvé N and Beyer J for the IGCCCG Update Consortium

Presentation number: 903O

Speaker: Silke Gillessen

Date: 28.09.2019 – Lecture time: 15:30 – 15:45 – Location: Sevilla Auditorium (Hall 2)

 

Poster

There is a lack of clinical research for patients with cancer in palliative care

M. Vinches, A. Neven, L. Fenwarth, M. Terada, G. Rossi, S. Kelly, J. Peron, M. Thomaso, M. Groenvold, T. De Rojas

Poster number: 1610P

Poster presenter: Marie Vinches

Date: 28.09.2019 – Lecture time: 12:20 – Location: Poster Area (Hall 4)

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023